Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4860 - Use of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC).

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Geriatric Oncology

Tumour Site

Breast Cancer

Presenters

Mariana Chavez Mac Gregor

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

M. Chavez Mac Gregor1, X. Lei2, H. Zhao2, C. van Poznak3, S.H. Giordano1

Author affiliations

  • 1 Breast Medical Oncology, Health Services Research, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Health Services Research, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Breast Medical Oncology, The University of Michigan, Ann Arbor/US
More

Resources

Abstract 4860

Background

BC patients who have evidence of bone metastases should be treated with BMAs in order to reduce skeletal related events. ONJ is a serious complication associated the use of BMAs. In this large population-based study we evaluate the patterns of use of BMAs and ONJ rates in a cohort of older BC patients.

Methods

Patients diagnosed with de novo metastatic BC between 2007-2013 were identified in the SEER-Medicare database. We identified the presence of bone metastases using specific PEDSF variables and claims. All patients were required to receive systemic anticancer therapy within one year of diagnosis. HCPCS codes were used to identify the use of BMAs within 1 year of cancer diagnosis, ONJ was identified using an established ICD-9 codes. Descriptive statistics and regression models were used.

Results

A total of 1,528 patients were included. The median age of the cohort was 74 yo. Within one year of diagnosis of bone metastases 71.1% of the patients received BMAs (68% bisphosphonates, 27% denosumab, 5% both). Older patients (OR = 0.64; 95%CI 0.46-0.89), those with more comorbidities (OR = 0.61; 95%CI 0.43-0.85) or with full/partial state buy-in (OR = 0.65; 95%CI 0.49-0.87) -surrogate for poverty- were less likely to receive BMAs. Nineteen cases of ONJ were identified, all of them occurred among BMAs-treated patients (1.7%), the 2-year and 4-year cumulative rates were 1.4% and 4.0%, respectively. Similar rates of ONJ were observed between patients treated with bisphosphonates and denosumab. Median duration of BMA therapy among patients who developed ONJ was 20 months (IQR 10-43). No clinical predictors of ONJ were identified.

Conclusions

In this large, nationally-representative cohort, the majority of the BC patients with evidence of bone metastases received treatment with BMA according to current guidelines. Similar rates of ONJ were observed among bisphosphonates and denosumab users. ONJ occurred in approximately 2% of this SEER-Medicare population of patients with BC and bone metastases treated with BMA. Our findings are of significant value since they reflect the patterns of care and complications associated with these commonly used agents in the general population.

Clinical trial identification

Legal entity responsible for the study

Mariana Cgavez Mac Gregor.

Funding

CERCIT, Sudan G. Komen.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.